Gilead Sciences (NASDAQ:GILD) Price Target Raised to $170.00

Gilead Sciences (NASDAQ:GILD) had its price target increased by Needham & Company LLC from $140.00 to $170.00 in a research note issued to investors on Wednesday morning, Marketbeat.com reports. They currently have a buy rating on the biopharmaceutical company’s stock.

GILD has been the topic of a number of other research reports. Scotiabank started coverage on Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price on the stock. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $100.00 to $103.00 and gave the company a “sector perform” rating in a research note on Tuesday, January 20th. Finally, HSBC boosted their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Twenty-three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $152.42.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $154.98 on Wednesday. Gilead Sciences has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The stock has a market cap of $192.28 billion, a PE ratio of 22.89, a price-to-earnings-growth ratio of 1.22 and a beta of 0.36. The business has a fifty day simple moving average of $130.27 and a 200-day simple moving average of $122.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts anticipate that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio is currently 46.68%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. This trade represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the sale, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 319,391 shares of company stock valued at $44,141,101. Corporate insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

A number of large investors have recently added to or reduced their stakes in GILD. Brighton Jones LLC boosted its holdings in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC acquired a new position in Gilead Sciences during the 4th quarter worth $215,000. Sivia Capital Partners LLC lifted its position in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 602 shares during the last quarter. Vest Financial LLC boosted its holdings in Gilead Sciences by 39.3% during the second quarter. Vest Financial LLC now owns 14,472 shares of the biopharmaceutical company’s stock valued at $1,605,000 after acquiring an additional 4,080 shares during the period. Finally, Cornerstone Wealth Group LLC grew its position in shares of Gilead Sciences by 20.1% in the second quarter. Cornerstone Wealth Group LLC now owns 2,822 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 472 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.